Imunon (LTS:0HUZ) Short-Term Capital Lease Obligation : $0.40 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Imunon Short-Term Capital Lease Obligation?

Imunon's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.40 Mil.

Imunon's quarterly Short-Term Capital Lease Obligation declined from Sep. 2024 ($0.51 Mil) to Dec. 2024 ($0.45 Mil) and declined from Dec. 2024 ($0.45 Mil) to Mar. 2025 ($0.40 Mil).

Imunon's annual Short-Term Capital Lease Obligation increased from Dec. 2022 ($0.23 Mil) to Dec. 2023 ($0.49 Mil) but then declined from Dec. 2023 ($0.49 Mil) to Dec. 2024 ($0.45 Mil).

Imunon Short-Term Capital Lease Obligation Historical Data

The historical data trend for Imunon's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Short-Term Capital Lease Obligation Chart

Imunon Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.43

0.55

0.23

0.49

0.45

Imunon Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.50	0.52	0.51	0.45	0.40

Imunon Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Imunon Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Imunon's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Imunon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (LTS:0HUZ) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

IMNN:USA CBO:Germany

Address

997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648

Website

https://www.imunon.com

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Imunon Headlines

No Headlines